Fulvestrant Injection
Product Images NDC 55150-394
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 18 technical images submitted to the FDA as part of the official labeling for Fulvestrant (NDC 55150-394). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Eugia Us Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Fulvestrant Figure10 (Fulvestrant Fig10)
Fulvestrant Figure11 (Fulvestrant Fig11)
Fulvestrant-fig12.jpg (Fulvestrant Fig12)
Fulvestrant-fig13.jpg (Fulvestrant Fig13)
Fulvestrant-fig14 (Fulvestrant Fig14)
Package Label.principal Display Panel 250 mg Per 5 mL (50 mg/ml) Syringe Label (Fulvestrant Fig15)
This is a description of a medication called Fulvestrant. It is an injection available in a prefilled syringe, with a concentration of 250 mg per 5 mL (50 mg per mL). It is meant for intramuscular use only and should be protected from light. The medication is manufactured in India for Eugia US LLC, located in E. Windsor, NJ 08520. There is also a code provided: TS/DRUGS/.*
Package Label-principal Display Panel (Peel off Patient Record Label)
This is a description of a medication called Fulvestrant Injection. It is available in a carton containing two single-dose prefilled syringes, each containing 250 mg of the medication. The syringes need to be administered together to receive the full 500 mg dose. The medication is to be refrigerated at 2 to 8 degrees Celsius and should be protected from light by storing it in the original carton until the time of use. The injection is to be administered intramuscularly, following local guidelines for performing large volume intramuscular injections. The package also contains two SafetyGlide™ shielding intramuscular injection needles. The injection should be administered into the buttock area slowly over 1 to 2 minutes. After administration, the lever arm on the syringe's needle should be activated to deploy the needle shielding. The empty syringe should be discarded in an approved sharps collector.*
Package Label-principal Display Panel (Peel off Patient Record Label)
Fulvestrant Figure2 (Fulvestrant Fig2)
Fulvestrant Figure3 (Fulvestrant Fig3)
Fulvestrant Figure4 (Fulvestrant Fig4)
Fulvestrant Figure5 (Fulvestrant Fig5)
Fulvestrant Figure6 (Fulvestrant Fig6)
Fulvestrant Figure7 (Fulvestrant Fig7)
Fulvestrant Figure8 (Fulvestrant Fig8)
Fulvestrant Figure9 (Fulvestrant Fig9)
Fulvestrant Structure (Fulvestrant Str)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.